The Kernicterus Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Kernicterus Treatment Market:
https://www.thebusinessresearchcompany.com/report/kernicterus-treatment-global-market-report
According to The Business Research Company’s Kernicterus Treatment Global Market Report 2024, The kernicterus treatment market size has grown steadily in recent years. It will grow from $2.88 billion in 2023 to $2.98 billion in 2024 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to improvements in neonatal care practices, increased awareness among healthcare professionals, government initiatives for maternal and child health, research funding and clinical trials, collaborations in medical research..
The kernicterus treatment market size is expected to see steady growth in the next few years. It will grow to $3.29 billion in 2028 at a compound annual growth rate (CAGR) of 2.6%. The growth in the forecast period can be attributed to continuous medical education programs, global health policies and initiatives, patient advocacy and support groups, international collaboration in pediatric research, government funding for neonatal health.. Major trends in the forecast period include advancements in neonatal jaundice monitoring technologies, introduction of phototherapy devices with enhanced features, development of bilirubin-reducing medications, focus on home-based phototherapy solutions, implementation of bilirubin nomograms and guidelines, integration of telehealth for remote monitoring..
The prevalence of neonatal jaundice is driving the growth of the kernicterus treatment market going forward. Neonatal jaundice, also known simply as jaundice in newborns, is a common and typically harmless condition characterized by the yellowing of a baby’s skin and the whites of their eyes. Kernicterus treatment is commonly used for neonatal jaundice; it manages the symptoms and provides supportive care. This procedure removes blood from the baby and replaces it with blood with a lower bilirubin level, improving the affected child’s quality of life. For instance, in August 2023, according to reports published by the National Library of Medicine, a US-based biomedical library, globally, about 1.1 million babies each year develop severe neonatal hyperbilirubinemia (neonatal jaundice). Furthermore, in February 2021, according to ClinMed International Library, a US-based publishing company, it was estimated that at least 114,000 infants die yearly from neonatal hyperbilirubinemia (neonatal jaundice). Therefore, the prevalence of neonatal jaundice is expected to propel the growth of the kernicterus treatment market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=13470&type=smp
The kernicterus treatment market covered in this report is segmented –
1) By Treatment: Phototherapy, Intravenous Immunoglobulins (IVIG), Blood Transfusion, Medication, Other Treatments
2) By Symptoms: Jaundice, Unusual Eye Movements, Vomiting, Fever, Poor Feeding, Apnoea, Irritability, Seizures, Sleepiness, Other Symptoms
3) By Dosage: Injection, Solution, Other Dosages
4) By End-Users: Clinic, Hospital, Other End-Users
Top Major Players:
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Merck and Co. Inc.
AbbVie Inc.
Bayer AG
North America was the largest region in the kernicterus treatment market in 2023.
Major institutes operating in the kernicterus treatment market are developing innovative technological products, such as wearable devices to monitor jaundice accurately, that help gain a competitive advantage. A wearable device is a small, flexible patch placed on the body according to the treatment requirement. For instance, in March 2021, Yokohama National University, a Japan-based university, designed the first-ever wearable device to accurately monitor jaundice, a yellowing of the skin due to increased bilirubin levels in the blood that can result in severe medical conditions in infants. This wearable sensor for infants can constantly measure bilirubin to achieve the intricate balance of administering the accurate amount of blue light required to neutralize the correct bilirubin levels. Moreover, it is a small, flexible patch that is placed on the infant’s chest, and it transmits data to a smartphone or computer, where doctors or parents can monitor it. Also, it is more accurate and convenient than traditional methods of monitoring jaundice, such as blood tests.
The kernicterus treatment market report table of contents includes:
1. Executive Summary
2. Kernicterus Treatment Market Characteristics
3. Kernicterus Treatment Market Trends And Strategies
4. Kernicterus Treatment Market – Macro Economic Scenario
5. Global Kernicterus Treatment Market Size and Growth
..
32. Global Kernicterus Treatment Market Competitive Benchmarking
33. Global Kernicterus Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Kernicterus Treatment Market
35.Kernicterus Treatment Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
